Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genetic Disorders Partnering 2012 to 2018 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Genetic Disorders partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Genetic Disorders partnering agreement structure

Genetic Disorders partnering contract documents

Top Genetic Disorders deals by value

Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2012. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2012 to 2018 includes:

Trends in Genetic Disorders dealmaking in the biopharma industry since 2012

Analysis of Genetic Disorders deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Genetic Disorders deal contract documents

Comprehensive access to over 3500 Genetic Disorders deal records

The leading Genetic Disorders deals by value since 2012

Most active Genetic Disorders dealmakers since 2012

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Genetic Disorders Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Genetic Disorders deal trends since 2012

Access Genetic Disorders deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Genetic Disorders partner companies

Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world's biopharma companies

Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Genetic Disorders opportunities

Uncover companies actively partnering Genetic Disorders opportunities

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking
2.1. Introduction
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering
3.1. Introduction
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers
4.1. Introduction
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory
5.1. Introduction
5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genetic Disorders therapeutic target

Appendices
Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Genetic Disorders deals by deal type 2012 to 2018
Appendix 3 - Directory of Genetic Disorders deals by stage of development 2012 to 2018
Appendix 4 - Directory of Genetic Disorders deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Genetic Disorders partnering since 2012
Figure 2: Genetic Disorders partnering by deal type since 2012
Figure 3: Genetic Disorders partnering by industry sector since 2012
Figure 4: Genetic Disorders partnering by stage of development since 2012
Figure 5: Genetic Disorders partnering by technology type since 2012
Figure 6: Genetic Disorders partnering by indication since 2012
Figure 7: Genetic Disorders deals with a headline value
Figure 8: Genetic Disorders deals with upfront payment values
Figure 9: Genetic Disorders deals with milestone payment
Figure 10: Genetic Disorders deals with royalty rates
Figure 11: Active Genetic Disorders dealmaking activity- 2012 to 2018
Figure 12: Top Genetic Disorders deals by value since 2012
  • Global Thyroid Gland Disorder Treatment Market Size, Status and Forecast 2019-2025
    Published: 12-Jul-2019        Price: US 3900 Onwards        Pages: 96
    Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing. Globally, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. Hyperthyroidism and hypothyroidism affect majority of the population primarily due to growing incidence of autoimmune diseases such as Grave's disease and Hashimoto's thyroiditis. Moreover, iodine deficiency is a widespread problem across the glob......
  • Global Hypertrophic Cardiomyopathy Therapeutics Industry Market Research Report
    Published: 11-Jul-2019        Price: US 2960 Onwards        Pages: 132
    The Hypertrophic Cardiomyopathy Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Hypertrophic Cardiomyopathy Therapeutics industrial chain, this report mainly elaborates the definition, types, applications and major players of Hypertrophic Cardiomyopathy Therapeutics market in details. Deep analysis about market status (2014-2019), enterprise competition patte......
  • Global Biologic Therapeutics Market Size, Status and Forecast 2019-2025
    Published: 11-Jul-2019        Price: US 3900 Onwards        Pages: 95
    Biologic therapeutics drugs are genetically engineered proteins derived from human genetic material. They contain sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. In addition, biologics drugs are derived from natural sources such as animals, humans, and microorganisms that are further utilized to make therapeutic products such as vaccines, blood components, and recombinant therapeutic proteins. First and for......
  • Global Neuromodulation Market Size, Status and Forecast 2019-2025
    Published: 11-Jul-2019        Price: US 3900 Onwards        Pages: 95
    Neuromodulation is the physiological process by which a given neuron uses one or more chemicals to regulate diverse populations of neurons. The key drivers for the growth of neuromodulation market include rise in geriatric population, their vulnerability for neurological disorders, increase in incidence of neurological diseases, such as Alzheimer's and Parkinson's diseases, and the increase in awareness regarding the safety and efficacy of neurostimulator devices. However, restrains, suc......
  • Global Immunology Market Size, Status and Forecast 2019-2025
    Published: 11-Jul-2019        Price: US 3900 Onwards        Pages: 96
    The immune system protects the body from harmful things such as a virus, germs, and diseases like cancer. It is a network of cells, molecules: and organs present throughout the body. The immune system attacks the foreign substance that is found in the body. The body identifies and destroys the abnormal cells including cancerous cells. The inherent self-defense system comprises cells, which help the body in the identification of foreign molecules. Different pathways regulate various immune cells ......
  • Global Hemoglobinopathies Market Growth (Status and Outlook) 2019-2024
    Published: 10-Jul-2019        Price: US 3660 Onwards        Pages: 115
    According to this study, over the next five years the Hemoglobinopathies market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Hemoglobinopathies business, shared in Chapter 3. This report presents a comprehensive overview, market shares and growth opportunities of Hemoglobinopathies market by product type, ap......
  • Global Gout Therapeutics Market Size, Status and Forecast 2019-2025
    Published: 09-Jul-2019        Price: US 3900 Onwards        Pages: 92
    Gout is a physical conditions that affects the patient's ability to move, often also termed as unwalkable disease, and it has been around for centuries. Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to patients on the basis of severity of the condition. Introduction of urate-lowering agents is one of the primary driver of the gout therapeutics market. First line therapies such as Febuxostat a......
  • Global Light Therapy Market Size, Status and Forecast 2019-2025
    Published: 09-Jul-2019        Price: US 3900 Onwards        Pages: 92
    Light therapy consists of exposure to daylight or to specific wavelengths of light using polychromatic polarised light, lasers, light-emitting diodes, fluorescent lamps, dichroic lamps or very bright, full-spectrum light. The light is administered for a prescribed amount of time and, in some cases, at a specific time of day. One common use of the term is associated with the treatment of skin disorders, chiefly psoriasis, acne vulgaris, eczema and neonatal jaundice. Light therapy which str......
  • Global Hypercalcemia Treatment Market Size, Status and Forecast 2019-2025
    Published: 09-Jul-2019        Price: US 3900 Onwards        Pages: 92
    Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma. The increasing instances of surgical procedures, such as hip and knee replacements, will increase the risk of hypercalcemia and drive the growth prospects for the globa......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs